KalVista Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Cash & Equivalents	213.77	229.34	131.62	31.79	56.24	30.73
Short-Term Investments	71.26	70.87	89	178.61	93.14	135.47
Cash & Short-Term Investments	285.03	300.21	220.62	210.4	149.38	166.2
Cash Growth	29.20%	36.08%	4.86%	40.85%	-10.12%	-33.23%
Accounts Receivable	9.9	2.59	-	-	-	-
Other Receivables	7.43	6.2	1.38	8.44	16.57	14.1
Total Trade Receivables	17.33	8.79	1.38	8.44	16.57	14.1
Inventory	4	3.43	-	-	-	-
Other Current Assets	7.85	7.71	19.69	6.85	6.38	13.35
Total Current Assets	314.21	320.15	241.69	225.69	172.33	193.65
Net Property, Plant & Equipment	12.26	12.86	7.53	9.15	10.77	10.04
Other Long-Term Assets	2.45	2.37	1.55	0.57	0.11	0.19
Total Assets	328.92	335.38	250.77	235.4	183.2	203.88
Accounts Payable	8.05	8.27	4.88	9.11	4.82	3.64
Accrued Expenses	34.02	33.9	27.31	12.4	9.13	6.96
Current Portion of Leases	1.69	1.62	1.98	1.3	1.09	0.98
Unearned Revenue	0.83	-	11	-	-	-
Other Current Liabilities	16.23	13.57	-	-	-	-
Total Current Liabilities	60.82	57.36	45.17	22.81	15.03	11.58
Long-Term Debt	139.4	139.23	-	-	-	-
Long-Term Leases	10.41	10.73	4.33	6.02	7.15	7.21
Other Long-Term Liabilities	137.94	130.78	105.88	-	-	-
Total Long-Term Liabilities	287.75	280.73	110.21	6.02	7.15	7.21
Total Liabilities	348.57	338.09	155.38	28.82	22.18	18.79
Common Stock	0.05	0.05	0.05	0.04	0.03	0.03
Additional Paid-in Capital	773.59	767.06	753.73	679.75	507.13	439.1
Accumulated Other Comprehensive Income	-7.12	-7.13	-5.21	-3.49	-3.06	-3.86
Retained Earnings	-786.18	-762.69	-653.17	-469.73	-343.08	-250.18
Shareholders' Equity	-19.65	-2.71	95.39	206.58	161.03	185.09
Total Liabilities & Equity	328.92	335.38	250.77	235.4	183.2	203.88
Total Debt	151.5	151.58	6.31	7.32	8.23	8.19
Net Cash (Debt)	133.53	148.64	214.31	203.08	141.14	158.01
Net Cash Growth	-10.17%	-30.64%	5.53%	43.89%	-10.68%	-34.98%
Net Cash Per Share	2.49	2.92	4.32	5.52	5.06	6.46
Book Value	-19.65	-2.71	95.39	206.58	161.03	185.09
Book Value Per Share	-0.37	-0.05	1.92	5.62	5.77	7.56
Tangible Book Value	-19.65	-2.71	95.39	206.58	161.03	185.09
Tangible Book Value Per Share	-0.37	-0.05	1.92	5.62	5.77	7.56

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q